Brand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit

Similar documents
Drug Class Prior Authorization Criteria Immune Globulins

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

Primary Diagnosis: Diagnosis Code(s) (if known): Individual s Weight (lbs) (kg)

Circle Yes or No Y N. [If yes, no further questions.]

Immune Globulins. Subcutaneous Immune Globulin: Cuvitru, Hizentra and HyQvia

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Intravenous Immune Globulins (IVIG)

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

The University of Mississippi Medical Center The University of Mississippi Health Care. Pharmacy and Therapeutics Committee Medication Use Evaluation

Immune Globulin Therapy

Clinical Policy: Immune Globulins Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid

IVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen

[If yes, no further questions.]

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Injectable Drugs Requiring Pre-Service Approval

MedStar Medicare Choice Pharmacy Services

See Important Reminder at the end of this policy for important regulatory and legal information.

Immune Globulin Therapy

Clinical Policy: Immune Globulins Reference Number: ERX.SPMN.129

Immune Globulin. Prior Authorization

See Important Reminder at the end of this policy for important regulatory and legal information.

Neuromuscular Blocking Agents

Botox. Botox (onabotulinum toxin A) Description

Pharmacy Services Request Types

IMMUNE GLOBULIN THERAPY

Immune Globulins Drug Class Prior Authorization Protocol

Intravenous Immune Globulin (IVIg)

POLICIES AND PROCEDURE MANUAL

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

SPECIALTY GUIDELINE MANAGEMENT

MEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection

Informed Consent Form

Cigna Drug and Biologic Coverage Policy

Xolair. Xolair (omalizumab) Description

Policy. Medical Policy Manual Approved: Do Not Implement Until 1/31/19. Intravenous Immune Globulin (IVIG) Therapy

Xolair. Xolair (omalizumab) Description

IVIG (Intravenous Immune Globulin) SCIG (Subcutaneous Immune Globulin)

Table of Contents. 1.0 Description of the Procedure, Product, or Service Safety and Provider Compliance... 1

BOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

IVIG Immune Globulin Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen

Pharmacy and Medical Guideline Updates

Immune Globulin. Clinical Overview Program BioScrip Inc. All rights reserved BioScrip Inc. All rights reserved.

Intravenous Immune Globulins (IVIG)

Aetna Better Health of Virginia

Prior Authorization Update: Botulinum Toxins

(Last Revised 10/04/18)

Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc )

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)

* Note: please reference the Highmark Health Options Gender Transition Services (MP- 033-MD-DE) policy for all gender dysphoria requests.

Medication Prior Authorization Form

POLICY Document for Intravenous Immune Globulin (IVIG)

See Important Reminder at the end of this policy for important regulatory and legal information.

3. Does the patient have a diagnosis of warm-type autoimmune hemolytic anemia?

BOTOX (onabotulinumtoxina) for Therapeutic Use

Immune Globulin Therapy

Immune Globulins Last Review Date: September 13, 2016 Number: MG.MM.PH.17av2 Medical Guideline Disclaimer Definition

1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Coverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010

2016 MDwise HIP Medical Services that Require Prior Authorization

List of Chapters. 5. Care of the sick child Evidence-based pediatrics (page 77 to 80)

Quick Reference: Plasma Protein Products

INDIANA HEALTH COVERAGE PROGRAMS

The proposal is to add text/statements in red and to delete text/statements with strikethrough: POLICY

xx Xolair 150 MG SOLR (GENENTECH)

Botox. Botox (onabotulinum toxin A) Description

Clinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:

PROBLEMS WITH THE IMMUNE SYSTEM. Blood Types, Transplants, Allergies, Autoimmune diseases, Immunodeficiency Diseases

Medication Prior Authorization Form

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

From: Plasma Protein Therapeutics Association (PPTA)

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

See Important Reminder at the end of this policy for important regulatory and legal information.

Botulinum Toxins. Length of Authorization: From 90 days to 12 months

Intravenous Immunoglobulin (IVIG)*

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

2017 Blue Cross and Blue Shield of Louisiana

DRUG USE EVALUATION: UTILIZATION OF BOTULINUM TOXIN

Corporate Medical Policy

Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication

XOLAIR (omalizumab) Prior Authorization

Evolving Uses of IVIG in myositis

Original Policy Date

Omalizumab (Xolair) NHLBI normal ranges by age for FEV 1/FVC 8-19 years of age 85%; years of age 80%;

Medication Prior Authorization Form

SPECIALTY PHARMACY Master Clinical Drug List

MERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS

Lumbosacral plexus lesion Lumbosacral plexus disorders G54.1 Neuralgic amyotrophy Neuralgic amyotrophy G

Corporate Medical Policy

IMMUNE GLOBULIN (IVIG AND SCIG)

See Important Reminder at the end of this policy for important regulatory and legal information.

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

Transcription:

Affinity Health Plan Department Of Pharmacy (Medicaid, Child Health Plus, Family Health Plus, Medicare Part B) **Medications Requiring Authorization under Medical Benefit** Click Here For Medication Authorization Request Form (please fax request to 718.536.3329) Brand Generic J-Code 1 Billable Unit Covered Uses Botox Onabotulinumtoxin A J0585 1 unit Primary axillary hyperhidrosis in adults Blepharospasm (>12 years old) Strabismus (>12 years old) Cervical Dystonia (>16 years old) Hemifacial Spasm Upper extremity spasticity Overactive bladder Neurogenic bladder Chronic migraine Spasticity related to Cerebral Palsy Achalasia Required Medical Information and Criteria Neurologic workup Trial of at least 3 classes of migraine Hyperhidrosis disease severity scale (HDSS) score Myobloc Rimabotulinumtoxin B J0587 100units Cervical Dystonia Neurologic workup with previous methods tried Dysport Abobotulinumtoxin A J0586 5 units Xeomin Incobotulinumtoxin A J0588 1 unit Blepharospasm Cervical Dystonia Cinryze J0598 Hereditary angioedema C1 esterase inhibitor (human) 10 units (HAE) (>12 years old) Berinert J0597 Previous medication trials Confirmed diagnosis of HAE by laboratory testing (Last Revised 5/2013) Exclusion Criteria Cosmetics uses Lower limb spasticity Diabetic neuropathic pain Emergency CABG

Firazyr Icatibant J1744 Kalbitor Ecallantide J1290 1 mg Acute attacks of HAE Laboratory confirmation of HAE Administered by appropriate health care specialist Caverject Alprostadil J0270 1.25 mcg Diagnosis of Erectile Dysfunction (ED) Muse Aplrostadil urethral J0275 125 mcg Complete physical examination. Treatment of ED Registered Sex Offender Male infertility Pavacot Papaverine J2440 60 mg Oraverse Phentolamine J2760 5 mg Lupron Depot Lupron Leuprolide J1950 J9217 3.75 mg 7.5 mg Central Precocious Puberty (CPP) Endometriosis Uterine leiomyomata with anemia Prostate Cancer (PC) Breast Cancer (BC) Ovarian Cancer Laboratory confirmation PC: PSA, Gleason score. BC: hormone receptor (+), CPP: GnRH test, bone age assessment, imaging of the brain, age. Delayed puberty for short stature Vantas Histrelin Implant J9225 50 mg Prostate Cancer (PC) Laboratory confirmation PSA, Gleason Score. Disease staging

Supprelin LA Histrelin Implant J9226 50 mg Central Precocious Puberty Laboratory confirmation GnRH test, bone age assessment, imaging of the brain, age. Age < 2 Delayed puberty Makena Hydroxyprogesterone Caproate J1725 1 mg Reduce the risk of preterm birth in women, with a singleton pregnancy, who has a history of singleton spontaneous preterm birth. Xolair Omalizumab J2357 5 mg Moderate to severe persistent asthma (+) skin test reactive to perennial aeroallergen Inadequately controlled by corticosteroids. Synagis (Seasonal usage November-March) Palivizumab 90378 50 mg Prevention of lower respiratory tract disease in infants at high risk for RSV o Chronic Lung Previous history of singleton pregnancy Previous history of spontaneous preterm birth. Compounded hydroxyprogester one preferred (No Authorization required) Provider can contact Alere directly at 800-999-0225 or fax 516-240-1577 Age > 12 y/o IgE level Body Weight Previous use/adherence to inhaled steroids and Long Acting Beta Agonist Gestational age Actual age < 24 months Short cervix Current or planned cerclage Allergy to peanuts Allergic rhinitis Latex Allergy Dosing outside manufacturer s recommendations according to body weight and IgE levels Hypersensitivity Cystic Fibrosis

Cytogam J0850 50 ml Privigen J1459 500 mg J1460 1 ml Immune Globulin Disease o Premature Infant o Congenital Abnormality of airway/neuromuscu lar Condition o Hemodynamically unstable chronic heart disease Primary Immune Deficiency: Congenital Agammaglobulinemia Hypogammaglobulinemia levels should be while patient is free from infection to pneumococcus, tetanus, and/or diphtheria Fibromyalgia Lyme Disease Pediatric Epilepsy Neuropathy Gammaplex J1557 500 mg infections -Authorizations trough IgG levels; documenting patient response to Ig. Hizentra J1559 100 mg Bone Marrow Gammaked J1561 500 mg Transplant: Bone Marrow Transplant Transplant Date of transplant, detailed patient history Gamunex Immune Globulin J1561 500 mg Kawasaki CBC Vivaglobin J1562 100 mg Serum ESR Serum C-reactive protein Serum LFTs Gammagard liquid J1566 500 mg

Octagam J1568 500 mg Hyperrho S/D J2788 50mcg/ 250 IU Carimune J1566 500mg Flebogamma J1572 500mg Secondary Immunodeficiency: Chronic Lymphocytic Leukemia with Hypogammaglobulinemia (CLL) B cell CLL Hematology: Idiopathic Thrombocytopenia Purpura (ITP) Prophylaxis of rubella during pregnancy Prophylaxis of hepatitis A Post-exposure varicella Total IgG levels Laboratory values used to confirm diagnosis Neurological Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Inflammatory Myopathies (Polymyositis, Dermatomyositis) Guillain-Barre Syndrome Myasthenia Gravis exacerbation Multifocal Motor Neuropathy Relapsing/Remitting Multiple Sclerosis Testing used to confirm diagnosis (examples: EMG, Nerve Conduction Study (NCS), muscle biopsy, MRI, CSF protein, Anti-Mag antibodies, Anti-GD1a, Anti-GD1b) Documentation of standard treatment tried/failed/contraindicat e Multifocal Motor Neuropathy Anti-GM 1 antibody results Miscellaneous Codes Unclassified Meds J3490 Requires review with clinical documentation

J3590 It is the policy of Affinity Health Plan to require prior authorization for medical claims for the following drugs when administered in an office or clinic setting: In addition, all drugs requested by nonparticipating providers shall require prior authorization i.e. Specialty Pharmacies. All drugs that are self-administered are covered as part of the Pharmacy Benefit. Prior authorization will be required in order to be covered as a Medical Benefit. Any drug that does not have the indication supported by FDA or Compendia requires authorization. Acceptable Compendia are Micromedex DrugDex and NCCN (National Comprehensive Cancer Network).